Mosterd, Charlotte M.
Bjornstad, Petter
van Raalte, Daniël H.
Article History
Received: 5 December 2019
Accepted: 11 April 2020
First Online: 30 April 2020
Compliance with ethical standards
:
: Charlotte M. Mosterd has no conflict of interest. Petter Bjornstad has acted as a consultant for Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, Novo Nordisk and Horizon Pharma. Petter Bjornstad also serves on the advisory board of XORTX. Daniel H. van Raalte. has acted as a consultant and received honoraria from Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk and Sanofi and has received research operating funds from the Boehringer Ingelheim–Eli Lilly Diabetes Alliance, MSD, AstraZeneca and Novo Nordisk.
: This article does not contain any studies with human participants performed by any of the authors.